Exploring Growth Opportunities In Astrazeneca plc ADR (NASDAQ: AZN)

Astrazeneca plc ADR (NASDAQ:AZN) shares, rose in value on Thursday, April 04, with the stock price up by 2.07% to the previous day’s close as strong demand from buyers drove the stock to $68.19.

Actively observing the price movement in the recent trading, the stock is buoying the session at $66.81. The value of beta (5-year monthly) is 0.17 whereas the PE ratio is 35.73 over 12-month period. Referring to stock’s 52-week performance, its high was $76.56, and the low was $60.47. On the whole, AZN has fluctuated by 5.22% over the past month.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The company’s Forward Dividend Ratio is 1.45, with its dividend yield at 2.13%. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be $1.25, which is expected to increase to $1.96 for fiscal year $3.88 and then to about $4.38 by fiscal year 2025. Data indicates that the EPS growth is expected to be 6.90% in 2025, while the next year’s EPS growth is forecast to be 12.90%.

Analysts have estimated the company’s revenue for the quarter at $12.01 billion, with a low estimate of $11.76 billion and a high estimate of $12.44 billion. According to the average forecast, sales growth in current quarter could jump up 13.80%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2025, the company’s y-o-y revenues would reach $50.76 billion, representing an increase of 10.80% from the revenues reported in the last year’s results.

Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were 1 upward and no downward review(s) in last seven days. We see that AZN’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium term indicators have put the stock in the category of Hold while long term indicators on average have been pointing out that it is a 50% Buy.

The stock’s technical analysis shows that the PEG ratio is about 2.73, with the price of AZN currently trading nearly 2.31% and 3.77% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 60.98, while the 7-day volatility ratio is showing 1.42% which for the 30-day chart, stands at 1.19%. Furthermore, Astrazeneca plc ADR (AZN)’s beta value is 0.53, and its average true range (ATR) is 1.05.

A comparison of Astrazeneca plc ADR (AZN) with its peers suggests the former has fared considerably weaker in the market. AZN showed an intraday change of 2.07% in today’s session so far, and over the past year, it shrunk by -2.45%%.

Data on historical trading for Astrazeneca plc ADR (NASDAQ:AZN) indicates that the trading volumes over the past 10 days have averaged 4.39 million and over the past 3 months, they’ve averaged 6.21 million. According to company’s latest data on outstanding shares, there are 3.10 billion shares outstanding.

Nearly 0.03% of Astrazeneca plc ADR’s shares belong to company insiders and institutional investors own 15.98% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 9.26 million shares as on Mar 15, 2024, resulting in a short ratio of 1.87. According to the data, the short interest in Astrazeneca plc ADR (AZN) stood at 0.34% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 8.92 million. The stock has risen by 1.25% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the AZN stock heading into the next quarter.